KRAS and neoplasm: In KRAS-mutant NSCLC cell lines, avutometinib also demonstrated synergistic activity in reducing tumor cell viability when combined with other agents, including sotorasib, adagrasib, the focal adhesion kinase inhibitor defactinib, and the mTOR inhibitor everolimus.